8-K: Aditxt Invests $1.5 Million in Evofem Biosciences via Convertible Note and Warrant

Aditxt, Inc. invests $1.5 million in Evofem Biosciences through a securities purchase agreement involving a convertible note and warrant, while temporarily waiving termination rights under the existing merger agreement.

Summary

• Aditxt, Inc. invested an additional $1.5 million in Evofem Biosciences, Inc. on April 8, 2025.
• The investment was made through a Securities Purchase Agreement, which included a senior subordinated convertible note with a principal amount of $2,307,692.31 and a warrant to purchase 149,850,150 shares of Evofem common stock.
• Aditxt funded $750,000 of the purchase price on April 8, 2025.
• The note accrues interest at 8% per annum, adjusting to 12% upon an Event of Default, and is convertible into Evofem common stock at $0.0154 per share, subject to adjustment.
• The note matures on April 8, 2028, unless earlier converted or redeemed.
• The warrant is exercisable at $0.0154 per share, subject to adjustment, for a term of five years and may be exercised on a cashless basis.
• Aditxt's ownership of Evofem common stock is limited to 9.99% after conversion or exercise.
• Evofem temporarily waived its termination right under the Amended and Restated Merger Agreement until April 16, 2025.
• If the full purchase price is not received by April 16, 2025, the principal amount of the note and the number of shares issuable upon exercise of the warrant will be adjusted accordingly.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document describes a financial transaction with both positive and negative aspects. The investment provides Evofem with capital, but the terms of the agreement also indicate potential risks and concerns.

Positives

• Aditxt's investment provides Evofem with additional capital.
• The convertible note structure allows Aditxt to potentially benefit from Evofem's future growth.
• The temporary waiver of the termination right provides stability to the merger agreement.

Negatives

• The investment is structured as senior subordinated debt, indicating a higher risk for Aditxt.
• The interest rate on the note increases to 12% upon an Event of Default, suggesting potential concerns about Evofem's financial stability.
• Aditxt's ownership is capped at 9.99%, limiting its potential upside from the investment.

Risks

• Evofem may experience an Event of Default, increasing the interest rate on the note to 12%.
• If the full purchase price is not received by April 16, 2025, the principal amount of the note and the number of shares issuable upon exercise of the warrant will be adjusted accordingly.
• The merger agreement could still be terminated if the conditions are not met by the extended deadline.

Future Outlook

The document outlines the terms of an investment and a temporary waiver related to a merger agreement, but does not provide specific forward-looking statements or guidance regarding the future performance of either company.

Management Comments

• There are no explicit management comments included in the document, only signatures from the CEOs of Aditxt and Evofem.

Industry Context

This announcement reflects a continued effort to finalize a merger in the biotech/pharmaceutical space, where companies often seek strategic partnerships and acquisitions to expand their pipelines and market reach. The investment provides Evofem with capital, while Aditxt gains potential upside through the convertible note and warrant.

Comparison to Industry Standards

• Convertible notes and warrants are common financing tools in the biotech industry, particularly for companies with limited access to traditional debt markets.
• The specific terms, such as interest rates and conversion prices, are deal-specific and depend on the company's financial condition, growth prospects, and the overall market environment.
• Comparable companies that have used similar financing structures include Sorrento Therapeutics, which issued convertible notes and warrants to raise capital for its pipeline development, and Cassava Sciences, which has utilized similar instruments to fund its Alzheimer's drug research.
• The 9.99% ownership limitation is a common provision to avoid triggering certain regulatory thresholds and reporting requirements.

Stakeholder Impact

• Shareholders of Evofem may be impacted by the potential dilution from the conversion of the note and exercise of the warrant.
• Employees of Evofem may benefit from the additional capital, which could support ongoing operations and research.
• Creditors of Evofem should be aware of the senior subordinated status of the note, which ranks behind other debt obligations.

Next Steps

• Evofem needs to hold the Company Shareholders Meeting no later than September 26, 2025.
• Aditxt needs to fund the remaining $750,000 of the purchase price by April 16, 2025.
• Evofem needs to seek approval of the Principal Market to list or designate for quotation the Conversion Shares and the Warrant Shares.

Key Dates

Keywords

Evofem Biosciences, Aditxt, Merger Agreement, Convertible Note, Warrant, Investment, Securities Purchase Agreement